



Construction of a Prediction Model for Voriconazole-Induced Hepatotoxicity based on Mixed-Effects Random Forest

**atwitterhandle** 

Associate Researcher *Zhejiang Lab* 

Danyang Tong



@TheInstituteDH #MEDINF023

## ) IN 2028


### 8 – 12 JULY 2023 | SYDNEY, AUSTRALIA

## Introduction

- Voriconazole is a triazole antifungal agent with strong antifungal activity against a variety of clinically important pathogens
- Voriconazole exhibits non-linear pharmacokinetics, and its metabolism is related to multiple factors
- Hepatotoxicity is one of the most concerned adverse drug reactions

#MEDINF023

Guidelines recommend the implementation of therapeutic drug monitoring and the control of plasma valley concentration within the range of 0.5-5.5mg/L



#### https://www.michiganmedicine.org/health-lab/troubling-trends-drug-induced-liver-damage

Barzán Y, Bustus R-H, G. PinachoD, Personalized Medicine for Ambiotics: The Role of Nanobiosensors in Therepeutic Drug Monitoring. Journal of Personalized Medicine. 2020:10(4):47. https://doi.org/10.3390/jpm/0040147 Chen K, Zhang XL, Ke XY, Du GH, Yang KY, Zhai SD, An YZ. Chen YL, Dong YL, Guo RC, He B, Jiang B, Xu XH, Yang HX, Yi ZM, Guideline. Steering C, Guideline Consensus Panel G. Individualized Medication of Variconazole: A Practice Guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society, Therapeutic Drug Monitoring 2018, 40(6): 663-674. 10.1097/td. 0000000000000561

### Recommendation 5

The trough blood concentration of VRZ is recommended to be maintained above 0.5 mg·L<sup>-1</sup> (1B, strong recommendation, moderate quality of evidence).

#### Summary of the Evidence

Voriconazole

N-N

HO

Patients whose VRZ trough blood concentration was  $\leq 0.5 \text{ mg} \cdot \text{L}^{-1}$  exhibited a lower rate of treatment response (RR = 0.49, 95% CI; 0.29-0.81, moderate quality ofevidence).30

#### **Recommendation 6**

The trough blood concentration of VRZ is recommended to be maintained below 5 mg·L<sup>-1</sup> for Chinese population (1B, strong recommendation, moderate quality of evidence).

#### Summary of the Evidence

Asian patients whose VRZ trough blood concentration was <5 mg·L<sup>-1</sup> exhibited a lower rate of hepatotoxicity (RR = 0.34, 95% CI: 0.13-0.87, moderate quality of evidence).30



BIOSENSOR


INMUNOASSAY

# NFO23

### 8 – 12 JULY 2023 | SYDNEY, AUSTRALIA

## Introduction


- Several studies suggest that even patients whose voriconazole plasma trough concentration is within the recommended range of guidelines will still experience hepatotoxicity
- Compared with ideal clinical trials, real-world data can generate real-world evidence that better reflects real-world drug treatment response
- A large number of real-world data on patients taking voriconazole have been accumulated in various medical institutions
- Machine learning and artificial intelligence technology can better mine the information in real-world data to perform various tasks including detection of adverse drug reactions



#### Framework for FDA's Real-World Evidence Program

- Use of Electronic Health Records in Clinical Investigations
- Real-World Data: Assessing Electronic Health Records and Medical Claims Data to Support Regulatory Decision-Making for Drug and Biological Products
- Data Standards for Drug and Biological Production Submissions Containing Real-World Data
- Real-World Data: Assessing Registries to Support Regulatory Decision-Making for
  Drug and Biological Products
- Considerations for the Use of Real-World Data and Real-World Evidence to Support
   Regulatory Decision-Making for Drug and Biological Products
- Submitting Documents Utilizing Real-World Data and Real-World Evidence to FDA for Drugs and Biologics
- Considerations for the Design and Conduct of Externally Controlled Trials for Drug
   and Biological Products
- Use of Real-World Evidence to Support Regulatory Decision-Making for Medical
   Devices
- Use of Real-World Data and Real-World Evidence to Support Effectiveness of New Animal Drugs





### @TheInstituteDH #MEDINF023


#### https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence

Wang L, Song Y, Wang H, Zhang X, Wang M, He J, Li S, Zhang L, Li K, Cao L. Advances of Artificial Intelligence in Anti-Cancer Drug Design: A Review of the Past Decade. Pharmaceuticals. 2023; 16(2):253 https://doi.org/10.32391/nb161070253

#### Observation of hepatotoxicity occurence in current cohort









## Methods-Model Construction

## Feature Selection

- Information value (IV) is one of the most useful technique to select important variables in a predictive model.
- We set three thresholds of IV for feature selection, which are 0.01, 0.05 and 0.1 respectively

$$IV = \sum (n_{non-event} - n_{event})/n_{all} \times WOE$$

$$WOE = \ln \frac{n_{non-event}}{n_{event}}$$

### Model Construction

- Mixed effect model is suitable for repeated measurement data
- Considering the potential nonlinear relationship between selected features, mixed effect random forest (MERF) was chosen for model construction

 $y_i = f(x_i) + b_i + e_i, b_i \sim N(0, B)$ 

## Model Evaluation

- Average precision, recall and fl scores from 5-fold cross validation were used for model evaluation
- The performance of MERF model were compared with RF, LR, and SVM models.

@TheInstituteDH

#MEDINF023








## Results

Feature Type	Feature Overview
Predictive time point	7929 predictive time point in total, of which 2229 occurred hepatotoxicity within 30 days after voriconazole administration.
Demography	Age (19-92, Mean: 54.05, Median: 55.00) of included patients.
Voriconazole drug administration	The total dose (0-83600, Mean: 888.50, Median: 400.00) and daily dose (0-1200, Mean: 325.60, Median: 400.00) of voriconazole exposure between the current predicted time point and the previous one.
Condition	Medical history of organ transplant (4268), liver disease (1455) including cirrhosis, failure, and tumor, lung disease (4115) including pulmonary infection and pneumonia, and other diseases related to voriconazole (981).
Procedure	Whether a surgical process occurs between the current predicted time point and the previous one, a total of 276 surgical procedures were included.
Drug exposure	Whether the drug exposure of a drug occurred between the current predicted time point and the previous one, a total of 280 drug according to their active components were included.
Laboratory examination	Summary of each laboratory examination between the current predicted time point and the previous one, a total of 407 laboratory examination were included.



## Results

Feature Set Feature Type	IV>0.01	IV>0.05	IV>0.1
Demography	Age	Age	Age
Voriconazole drug administration	Total Dose and Daily Dose	Total Dose	/
Condition	4	2	/
Drug exposure	34	10	4
Laboratory examination	106	21	14
Total	147	35	19



Models constructed with different feature sets





# Conclusion

- A model for predicting occurrence of hepatotoxicity within 30 days of patients who used voriconazole and received TDM during hospitalization was built based on EHR data
- The model considering mixed effects showed considerable performance according to internal 5-fold cross-validation and better performance than conventional machine learning models
- Further multi-center validation and generalization test is necessary to transfer current work into clinical use